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Single cel l  molecular  t ools have been developed at  an incredible pace over t he last  f ive years as sequencing cost s cont inue t o drop
and numerous molecular  assays have been coupled t o sequencing readout s.  This rapid per iod of  t echnological  development  has
f aci l i t at ed t he del ineat ion of  individual  molecular  charact er ist ics including t he genome,  t ranscr ipt ome,  epigenome,  and prot eome
of  individual  cel ls,  leading t o an unprecedent ed resolut ion of  t he molecular  net works governing complex biological  syst ems.  The
immense power  of  single cel l  molecular  screens has been par t icular l y highl ight ed t hrough work in syst ems where cel lular
het erogenei t y is a key f eat ure,  such as st em cel l  biology,  immunology,  and t umor cel l  biology.  Single cel l  -omics t echnologies have
al ready cont r ibut ed t o t he ident i f icat ion of  novel  disease biomarkers,  cel lular  subset s,  t herapeut ic t arget s and diagnost ics,  many
of  which would have been undet ect able by bulk sequencing approaches.  More recent ly,  ef f or t s t o int egrat e single cel l  mul t i -omics
wit h single cel l  f unct ional  out put  and/ or  physical  locat ion have been chal lenging but  have led t o subst ant ial  advances.  Perhaps most
exci t ingly,  t here are emerging oppor t uni t ies t o reach beyond t he descr ipt ion of  st at ic cel lular  st at es wi t h recent  advances in
modulat ion of  cel l s t hrough CRISPR t echnology,  in par t icular  wi t h t he development  of  base edi t ors which great ly raises t he prospect
of  cel l  and gene t herapies.  In t his review,  we provide a br ief  overview of  emerging single cel l  t echnologies and discuss cur rent
development s in int egrat ing single cel l  molecular  screens and perf orming single cel l  mul t i -omics f or  cl inical  appl icat ions.  We also
discuss how single cel l  molecular assays can be useful ly combined wi t h f unct ional  dat a t o unpick t he mechanism of  cel lular  decision-
making.  Final l y,  we wi l l  ref lect  upon t he int roduct ion of  spat ial  t ranscr ipt omics and prot eomics,  i t s complement ary role wi t h
single cel l  RNA sequencing (scRNA-seq) and pot ent ial  appl icat ion in cel lular and gene t herapy.
  
 
Cont ribut ion to the f ield
The recent  rapid development  of  single cel l  t echnologies has revolut ionised our  underst anding of  t he molecular  net works dr iving
bot h normal  t issue biology and disease-speci f ic processes.  The unprecedent ed det ai l  in which t he genome,  t ranscr ipt ome,
epigenome and prot eome of  single cel ls can now be inspect ed has al lowed researchers t o develop more complex concept ual  models.
This has enabled t he discovery of  novel  cel l  t ypes,  disease-relat ed pat hways,  prot eins,  and much more.  The int egrat ion of  single cel l
t echniques int o mul t imodal  screens has provided an unprecedent ed insight  int o syst ems biology across mul t iple molecular
dimensions.  Real ising t he pot ent ial  of  t hese t echniques t o inf orm bot h t he development  of  novel  t herapeut ics and t he f ur t her
ref inement  of  current  cl inical  pract ices,  we propose how researchers and cl inicians can use single cel l  t echnologies t o advance t he
f ields of  gene and cel l  t herapy.  We make t he case t hat  as t he cost s associat ed wi t h t hese exper iment s decrease and t he
comput at ional  resources become more widely avai lable,  single cel l  approaches wi l l  become st andard pract ice f or  answer ing
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Single-cell molecular tools have been developed at an incredible pace over the last five 19 
years as sequencing costs continue to drop and numerous molecular assays have been 20 
coupled to sequencing readouts. This rapid period of technological development has 21 
facilitated the delineation of individual molecular characteristics including the genome, 22 
transcriptome, epigenome, and proteome of individual cells, leading to an unprecedented 23 
resolution of the molecular networks governing complex biological systems. The immense 24 
power of single-cell molecular screens has been particularly highlighted through work in 25 
systems where cellular heterogeneity is a key feature, such as stem cell biology, 26 
immunology, and tumor cell biology. Single-cell -omics technologies have already 27 
contributed to the identification of novel disease biomarkers, cellular subsets, therapeutic 28 
targets and diagnostics, many of which would have been undetectable by bulk sequencing 29 
approaches. More recently, efforts to integrate single-cell multi-omics with single cell 30 
functional output and/or physical location have been challenging but have led to substantial 31 
advances. Perhaps most excitingly, there are emerging opportunities to reach beyond the 32 
description of static cellular states with recent advances in modulation of cells through 33 
CRISPR technology, in particular with the development of base editors which greatly raises 34 
the prospect of cell and gene therapies. In this review, we provide a brief overview of 35 
emerging single-cell technologies and discuss current developments in integrating single-cell 36 
molecular screens and performing single-cell multi-omics for clinical applications. We also 37 
discuss how single-cell molecular assays can be usefully combined with functional data to 38 
unpick the mechanism of cellular decision-making. Finally, we will reflect upon the 39 
introduction of spatial transcriptomics and proteomics, its complementary role with single-cell 40 




























The crucial role that single-cell approaches play in understanding cell function has been 66 
recognised for decades. Early advances in immunology, and particularly hematopoiesis, 67 
have demonstrated the power of such approaches for ascribing functional properties to a 68 
single cell. Pioneering work by Till and McCulloch uncovered functional heterogeneity of 69 
hematopoietic stem cells (HSCs) by performing single cell-derived assays termed colony-70 
forming unit spleen, or CFU-S, assays (1,2). Similarly, early studies of single multipotent 71 
progenitors provided insights into the progenitor cell commitment and the development of 72 
mature immune cells, such as T and B lymphocytes (3,4). Perhaps most transformative was 73 
the introduction of fluorescence activated cell sorting (FACS) which enabled the near-74 
ubiquitous adaption of single-cell functional assays in immunology, hematopoiesis, and 75 
beyond (5–7). 76 
 77 
Efforts to characterize the cellular function of single cells have fuelled an increased desire to 78 
understand detailed molecular mechanisms, but the technologies to do so in single cells 79 
have lagged substantially. The development of the polymerase chain reaction (PCR) for 80 
amplifying DNA ultimately paved the way for the first glimpse into the transcriptome of single 81 
cells (8,9). The initial protocol for the amplification of cDNA using PCR from single 82 
macrophages was introduced by Brady et al., (10) where robust exponential amplification 83 
was achieved without disturbing the relative abundance of mRNA sequences, enabling the 84 
inspection of rare transcripts in a complex single cell-derived cDNA library. In parallel, 85 
Eberwine and colleagues developed a linear RNA amplification approach, based on the 86 
amplification of antisense RNA using a T7 RNA polymerase (11,12). By inspecting mRNAs 87 
from single pyramidal neurons isolated from rat brains, they provided the first evidence for 88 
global molecular heterogeneity between morphologically similar cells (11). 89 
 90 
While targeted single-cell PCR-based molecular screens revolutionized molecular biology, 91 
the low throughput and hypothesis-driven nature prevented unbiased exploratory screening. 92 
In 1991, Fodor and colleagues developed a novel photolithography-based approach for 93 
efficient synthesis of complex oligonucleotides on the microscale (13). This pioneering work 94 
would lead to the development of microarray technology where several years later, Schena 95 
et al. first applied this method for monitoring gene expression, examining the expression of 96 
45 Arabidopsis genes from total mRNA (14). The following decade saw a rapid expansion of 97 
the technology, resulting in genome-wide genomic, transcriptomic and epigenetic screening 98 
using microarrays (reviewed elsewhere: (15–18)). This ultimately enabled microarray 99 
analysis at single cell level (19), leading to insights into the molecular pathways governing 100 
cell fate (20,21).  101 
 102 
Microarrays, a hybridisation-based approach, assayed the known transcriptome and was 103 
therefore unsuitable for unbiased detection of novel transcripts. In 1977, Sanger and 104 
colleagues published the first genome to be sequenced (22) and soon after early generation 105 
sequencing methods began to rapidly develop (23). However, these approaches were 106 
extremely costly and time consuming (23). This opened up space for next generation 107 
sequencing (NGS) to lead to a revolution in molecular profiling, enabling low-cost, high-108 
throughput and highly parallelised sequencing of nucleic acids. To date, a wide variety of 109 
NGS platforms have been developed (reviewed in (24,25)) and in all cases, sheared DNA is 110 




synthesis of complementary DNA fragments for subsequent amplification (26). By using 112 
fluorophore-labelled nucleotides and simultaneous fluorescence readouts across the entire 113 
flow cell, the respective sequences can be determined and ultimately mapped against the 114 
reference genome (24,27,28). NGS for routine DNA and RNA sequencing provides multiple 115 
advantages over microarray technology, including reduced background noise, an increased 116 
dynamic range and the detection of novel transcripts (25,29,30).  117 
 118 
For these reasons, NGS was rapidly adapted to a variety of model systems, including the 119 
inspection of rare cell types at single cell resolution (31–36). Tang et al. pioneered the first 120 
protocol for single-cell RNA sequencing (scRNA-seq) in single mouse blastomeres with 121 
improved performance compared to microarray-based single-cell protocols (36). Following 122 
this there has been an explosion of single-cell molecular technologies, enabling unbiased 123 
screening of the transcriptome (37,38), genome (39,40), DNA methylation (41), chromatin 124 
accessibility (42) and spatial resolution of gene expression (43). While these methods 125 
provide comprehensive snapshots of molecular states, their integration with cellular 126 
phenotype and function is less common and remains vital to the inspection of tissue 127 
complexity, disease progression, therapeutic intervention, and beyond. To achieve this goal, 128 
pioneering work to integrate omics protocols led to the development of several multimodal 129 
technologies. These include simultaneous screening of I) cell surface proteins and mRNA 130 
(44,45), II) DNA methylation and mRNA (46), III) perturbations and mRNA (47), IV) DNA and 131 
mRNA (48), V) lineage tracing and mRNA, and VI) cellular function and mRNA  (44,49,50). 132 
 133 
Single-cell technologies have thus provided insight into a wide-range of disease 134 
mechanisms, especially in illnesses with significant heterogeneity (51), leading to a long list 135 
of potential new therapeutic options. In recent years, the fields of cellular and gene therapy 136 
have been steadily evolving for treatment of some monogenic diseases (gene therapy) and 137 
B cell leukemias (cell therapy) in particular (52,53). However, to enable further 138 
improvements and applications to other more complex disease types such as autoimmune 139 
type 1 diabetes, key aspects such as characterizing target tissues, identifying novel targets 140 
in heterogeneous diseases and assessing efficacy of therapeutic interventions all require 141 
deeper interrogation. Recent advances in single-cell technologies are ideally positioned to 142 
address a number of these unmet needs (51).  143 
 144 
In this review, we outline a wide range of recent technologies for screening the genome, 145 
epigenome, transcriptome and proteome of single cells and the multimodal integration of 146 
these platforms. We focus on the integration of functional cellular phenotypes with molecular 147 
















A golden age for gene therapy - recent successes in treating monogenic disorders 161 
 162 
In its simplest form, gene therapy aims to cure a patient’s disease by introducing a normal or 163 
corrected copy of a gene into target cells. In 1972, Friedmann and Roblin first proposed the 164 
concept of gene therapy as a treatment for inherited genetic defects that largely affected 165 
children, many of whom experienced severe, life-threatening symptoms (54). Initially, HSC 166 
transplantation represented the primary curative option for many of these disorders, but the 167 
availability of matched sibling donors and the risk of severe graft-versus-host disease were 168 
barriers for many patients (55). To circumvent these issues, the first gene therapy clinical 169 
trials used patient-derived differentiated (T lymphocytes) or immature (hematopoietic stem 170 
and progenitor cells, HSPCs) cells that were engineered ex vivo to express a disease-171 
correcting transgene (56,57). Pioneering studies in the late 1990s and early 2000s initially 172 
reported successful treatment of adenosine deaminase-deficient severe combined 173 
immunodeficiency (ADA-SCID) and other hematological disorders (56–59); however, these 174 
successes were soon overshadowed by reports of patients who experienced significant 175 
adverse events including the development of treatment-related leukemias and severe 176 
immune reactions (60–65). Many of these unanticipated biological effects were later directly 177 
linked to the viral vectors used for transgene delivery (66,67). Consequently, research efforts 178 
became focused on improving the safety of viral vectors (68–70) and monitoring for pre-179 
leukemic mutations became a standard feature of treatment follow-up (71–74). 180 
 181 
Following these improvements, a number of clinical trials have demonstrated the long-term 182 
benefits achieved in individuals with various primary immunodeficiencies and monogenic 183 
blood disorders who have received gene therapy treatments (75–84). The follow-up data 184 
being reported for these patients mainly focus on disease-relevant parameters such as blood 185 
counts and overall clinical symptoms. As a result, numerous questions related to the gene 186 
therapy process still remain (Figure 1). For example, which HSPC populations are readily 187 
transduced during drug product creation and how does this impact outcomes? Do gene 188 
corrected terminally differentiated cells have any advantage over their non-transduced 189 
counterparts? These types of questions can best be answered using single-cell 190 
technologies. Another area of active research involves the development of in vivo non-viral 191 
delivery systems. These strategies include the use of nanoparticles, 192 
aptamers/oligonucleotides and extracellular vesicles to deliver transgenes or 193 
siRNAs/shRNAs (85–90). While in vivo treatments circumvent issues related to the isolation 194 
and manipulation of target cells, they have the potential to induce expression of transgenes 195 
or siRNAs/shRNAs in cell types that are not relevant to curing disease. High resolution 196 
single-cell transcriptomic and proteomic data will be vital in dissecting how these new 197 
treatments affect cell populations receiving the correcting vector. These types of information, 198 
especially at the level of preclinical studies, will greatly aid in the development of these 199 
technologies.  200 
 201 
Moving beyond monogenic disorders, multi-target approaches may be useful in treating 202 
complex acquired diseases, such as cancers or autoimmune diseases like type 1 diabetes. 203 
Large-scale bulk pan-cancer genomics studies have suggested that tumors harbour an 204 
average of 4-5 driver mutations (91–94). While this represents an opportunity for the 205 
simultaneous manipulation of multiple drivers, the efficacy of this approach in individual 206 




subpopulations. As most genetic profiling of tumors is done using bulk sequencing, the 208 
resolution of major/minor clones and subclones becomes very difficult without the use of 209 
single-cell approaches. If individual cancers could be profiled to such high resolution, gene 210 
therapy strategies could be imagined to target genes essential to cancer cell survival (95–211 
98) or disrupt processes such as angiogenesis that facilitate tumor growth (99–102). 212 
Combination therapies may also prove to be highly effective in some contexts (103,104).  213 
 214 
Type 1 diabetes is an autoimmune disease driven by loss of T cell tolerance resulting in islet 215 
autoimmunity. During disease development, insulin-producing β-cells in the pancreas are 216 
abnormally targeted by infiltrating immune cells (105). For monogenic disorders such as 217 
immune dysregulation polyendocrinopathy enteropathy X-linked syndrome where patients 218 
are at a much higher risk of developing secondary type 1 diabetes, gene therapy treatment 219 
could offer a potential cure (106). However, the genetic drivers of primary type 1 diabetes 220 
are complex and may act at the level of β-cells themselves and/or various T cell populations 221 
(105). Preclinical studies exploring the use of gene therapy to treat type 1 diabetes have 222 
clearly demonstrated the need for treatments that function on two levels - one to create or 223 
maintain functional insulin-secreting β-cells and another to protect these cells from 224 
autoimmune responses (107–110). Regardless of disease context, the overall diversity of 225 
cellular interactions driving human disease presents many challenges to the development of 226 
successful treatments. Single-cell studies can address questions pertaining to cell type 227 
interactions, disease-specific immunity, clonal dynamics of gene corrected cells and therapy-228 
escape mechanisms, moving gene therapy forward to the next level. 229 
 230 
Cell therapy as a promising treatment for more complex diseases 231 
 232 
While gene therapy has revolutionized the treatment of primary immunodeficiencies and 233 
monogenic disorders, other strategies may be required to treat more complex diseases. 234 
Currently, the primary standard of care for many cancers is chemotherapy, radiation therapy 235 
or, in the case of solid tumors, surgery. Immune-based treatments including cell therapy and 236 
immune checkpoint inhibitors are now being developed, already showing promise in treating 237 
refractory or relapsed patient cohorts. Cell therapy strategies involving chimeric antigen 238 
receptor (CAR) T cells have been particularly successful in the treatment of B-cell 239 
malignancies (111–113). In brief, these therapies use autologous lymphocytes with 240 
synthetically engineered antigen receptors to target tumor-specific antigens (114), thereby 241 
harnessing the immune system to trigger anti-tumor immunity (Figure 2). Pioneering work by 242 
several groups led to the first successful application of this technology in the treatment of B-243 
cell malignancies (111–113), with the first therapy approved by the US-FDA in 2017 for use 244 
in B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma (115). 245 
 246 
Although stable remission is reportedly achieved in approximately 40-60% of patients with 247 
these B-cell malignancies (116), a number of significant barriers to increasing treatment 248 
efficacy have been identified. CAR T cell persistence and expansion has been shown to be 249 
variable between patients. Researchers have suggested that the use of less differentiated T 250 
cell subsets or T cells with an altered genetic background (for example, TET2 disruption) 251 
during the manufacturing phase may improve outcomes (115,117–123). However, a better 252 
understanding of the key molecular drivers of T cell expansion and persistence is required to 253 
inform future efforts to tailor the production of CAR T cells. Single-cell technologies can be 254 




overall performance of CAR T cells, another key aspect required to improve therapeutic 256 
outcomes is to control immune responses not directly mediated by CAR T cells 257 
(112,113,124,125). In order to minimise these responses, a more thorough understanding of 258 
immune cell interactions must first be developed. In this context, single-cell approaches will 259 
provide the resolution required to dissect these complex systems. On a different level, 260 
selective pressures applied by anti-CD19 CAR T cells may also lead to antigen escape and 261 
lineage switching as 10-25% of patients go on to develop a CD19- cancer (126). While 262 
groups reported acquired CD19 loss-of-function mutations (127) and abnormal splicing 263 
events leading to loss of CD19 expression (128,129), the specific origin of CD19- cancer 264 
cells was not clear. A recent paper using single-cell techniques provides evidence that in at 265 
least some patients, treatment-resistant CD19- cancer cells exist prior to treatment (130), 266 
underscoring the vital role of single-cell approaches pinpointing the mechanisms by which 267 
cancer cells escape treatment and informing strategies targeting refractory disease.  268 
 269 
On the other hand, there has been relatively limited success seen in CAR T cell treatments 270 
outside of B cell malignancies, despite the development of therapeutics targeting multiple 271 
antigens simultaneously or sequentially (reviewed in (131–133)). In solid cancers, tumor-272 
specific antigens (TSAs) first need to be comprehensively profiled to allow for selection of 273 
appropriate candidate TSAs (134) which is especially important when dealing with 274 
heterogeneous tumors. Understanding the consequences of on-target/off-tumor effects is 275 
also essential to creating safe and effective therapies as evidenced by recent reports of 276 
adverse events experienced by patients in two separate cell therapy clinical trials (135,136). 277 
Even once promising TSAs have been selected and tested in both animal models and early 278 
phase clinical trials, a number of other tumor-specific factors will likely interfere with the 279 
effectiveness of this treatment strategy. For example, immunosuppressive mechanisms that 280 
dampen T cell anti-tumor responses may also impact CAR T cell function. Combination 281 
therapies or further disruptions to create CAR T cells that are resistant to these immune 282 
evasion pathways may therefore become essential (137,138). Other CAR immune cell 283 
populations such as B cells, natural killer (NK) cells and macrophages may also be useful in 284 
treating certain diseases (139–141).  285 
 286 
In the context of diabetes, both CAR T cell and regulatory T cell-based treatments are 287 
currently being developed (142–147). Under normal conditions, Tregs mediate immune 288 
tolerance by expressing anti-inflammatory cytokines and dampening the inflammatory or 289 
cytotoxic responses of other types of T lymphocytes (148). While patients with type 1 290 
diabetes have similar frequencies of Tregs compared to control individuals, it has been 291 
shown that these Tregs have reduced immunosuppressive capacity (149–151). Adoptive 292 
Treg transfers from healthy donors into patients have shown promise in preclinical models 293 
for a number of different diseases driven by immune dysregulation including type 1 diabetes 294 
(152–158). However, a thorough understanding of the heterogeneous cell types that 295 
facilitate disease initiation and progression will be crucial to optimize these treatment 296 
regimens. 297 
 298 
Using single-cell approaches to refine treatment and inform the development of novel 299 
therapeutics 300 
 301 
Although great strides have been made in gene and cell therapy, applications to a wider 302 




tissues, identifying novel targets in heterogeneous diseases and assessing efficacy of 304 
therapeutic interventions require deeper interrogation and single-cell approaches are well-305 
positioned to provide this information.  306 
 307 
While a number of groups have begun to use single-cell approaches to dissect various 308 
aspects of CAR T cell-based therapy (130,159,160), the gene therapy field has not explored 309 
this to the same extent. That said, a handful of studies have used bulk sequencing 310 
approaches to examine post-transplantation clonal dynamics in a small number of patients 311 
(161–163). Biasco and colleagues used this approach to estimate transduced HSPC 312 
population size and describe the contributions of HSPC subpopulations to various stages of 313 
hematopoietic reconstitution (161,162). Most recently, Six and colleagues addressed 314 
questions pertaining to clonal selection following gene therapy in WAS, sickle cell disease 315 
(SCD) or beta-thalassemia patients and found no indications of clonal skewing caused by 316 
insertional mutagenesis (163). While all three of these studies provide important insights into 317 
human hematopoiesis, the reliance on bulk sequencing approaches to map viral integration 318 
sites means that several key questions remain unanswerable. For example, these methods 319 
do not allow unedited cells or low abundance clones to be tracked or the effects of multiple 320 
integration sites to be assessed. Furthermore, relationships between transduced and non-321 
transduced cells cannot be assayed. These details can only be examined using strategies 322 
that analyse single cells and their clonal progeny (164). 323 
 324 
In contrast, studies employing single-cell technologies have already begun to deconstruct 325 
the fundamental biology behind anti-CD19 CAR T cell therapeutic outcomes. Shieh et al. 326 
used single-cell transcriptomics to identify gene signatures associated with good treatment 327 
outcomes for patients with B cell malignancies, providing insights relevant to the optimisation 328 
of CAR T cell production (159). Deng et al. used a similar approach to discover 329 
transcriptional signatures connected to both complete and poor treatment responses (160). 330 
This study also identified a novel, transcriptionally distinct, cell population found specifically 331 
in the infusion products of patients who went on to develop high-grade immune effector cell-332 
associated neurotoxicity syndrome (160). This finding demonstrates the value of single-cell 333 
approaches in generating essential information that can then be fed back into clinical 334 
practice. Another recent publication applying single-cell technologies reported that the 335 
disease-driving clone observed in one patient’s relapsed B cell acute lymphoblastic leukemia 336 
existed prior to anti-CD19 CAR T treatment (130). Taken together, these studies clearly 337 
illustrate how single cell-based datasets can provide clinically relevant insights into various 338 
aspects of the cell therapy process (Figure 2).  339 
 340 
For every stage of the gene and cell therapy process, a number of important questions 341 
remain unanswered (Table 1). Ultimately, single-cell approaches will be instrumental both in 342 
informing our understanding of human disease and in developing the effective therapeutics 343 
required to treat them. Data generated using these methods has the potential to better 344 
inform our understanding of the numerous complex factors influencing treatment outcomes. 345 
The generation of novel targets and delivery methods for heterogeneous diseases relies on 346 
a high level of detail and the ability to map cell-cell interactions, especially for disorders with 347 
a strong immune component.  348 
 349 





A wide array of screening platforms have been developed to interrogate molecular states at 352 
the single cell level to give insight into tumor heterogeneity and clonal evolution of complex 353 
tissues. Here, we describe a selection of the most widely used omics tools and discuss their 354 
application in gene or cell therapy, including their potential role in addressing future clinical 355 
challenges.  356 
 357 
Genome. The first protocol for DNA sequencing at the single cell level, termed single 358 
nucleus sequencing (SNS), was described by Navin and colleagues (40). Comparable and 359 
reproducible detection levels of copy number variations were observed in single cell and bulk 360 
(106) samples. By sequencing the genomes of 100 single monogenomic breast tumor cells 361 
and the associated liver metastatic tissue, the authors also observed substantial clonal 362 
heterogeneity (40). After FACS of single nuclei and whole genome amplification (WGA), 363 
each nucleus is sequenced in an individual flow lane. The requirement of full sequencing 364 
lanes for single nuclei limited the throughput of such experiments and consequently, several 365 
groups introduced barcoding technologies to permit multiplexing of single cells in a single 366 
sequencing lane (165–169). To address this challenge, Amini et al. developed a 367 
combinatorial barcoding approach, first using Tn5 transposome-mediated labelling followed 368 
by PCR-based indexing to yield nearly 10,000 unique barcodes (167). In turn, Vitak et al. 369 
demonstrated the efficacy of a single-cell combinatorial indexed sequencing (SCI-seq) 370 
platform, by acquiring >1500 single cell genomes from a primary pancreatic ductal 371 
adenocarcinoma sample (39). To date, a multitude of single-cell sequencing platforms rely 372 
on these barcoding principles (170,171), however, only ~32% of sequenced cells had 373 
sufficient coverage for copy-number variation (CNV) detection (39). To address this issue 374 
and avoid amplification biases of exponential WGA, Chen and colleagues developed a linear 375 
amplification protocol, significantly reducing the required resolution for CNV calling  and this 376 
was further complemented by experimental and computational approaches to improve the 377 
detection of single nucleotide variants (172,173).  378 
 379 
Despite experimental drawbacks related to coverage, single-cell whole genome sequencing 380 
(scWGS) has enabled an unprecedented insight into clonal dynamics during tumorigenesis 381 
and normal hematopoiesis (174,175). One notable example includes a temporal study of 382 
single human B lymphocytes that explored the evolution of mutational signatures and age-383 
related accumulation of oncogenic mutations (176), only achievable through scWGS. 384 
 385 
While bulk WGS studies can infer which disease-causing mutations co-occur based on 386 
average variant allele frequencies, there is the potential to group populations of cells that in 387 
reality are part of distinct clonal entities. scWGS provides a more precise overview of clonal 388 
subpopulations while also capturing information that can be used to pinpoint mutation co-389 
occurrence and order of acquisition (177–181). This approach has been used to profile 390 
mutant clones in diseases such as childhood acute lymphoblastic leukemia, childhood T cell 391 
acute lymphoblastic leukemia and adult acute myeloid leukemia (182–184). Rare cancer cell 392 
populations missed in bulk WGS may also be detected in scWGS assays, as demonstrated 393 
by Xu and colleagues (184). Capturing this heterogeneity is essential to understanding how 394 
clones with certain mutational profiles impact disease evolution and response to treatment. 395 
 396 
Once gene corrected cells have been infused into a patient receiving gene therapy, it is 397 
important to track the clonal evolution of these corrected cells. scWGS could be used to 398 




mutations are acquired in cells during the gene therapy process. While this method is 400 
particularly effective at identifying copy number variants and aneuploidy, technical 401 
challenges exist such as low read coverage and sequencing depth. This may significantly 402 
hamper efforts to profile single nucleotide changes in gene corrected cells. For HSPCs, bulk 403 
WGS of single cell-derived clonal cultures or colonies has bypassed these obstacles (185); 404 
however, this approach is not feasible for cell types where ex vivo expansion is not possible. 405 
Provided that technical challenges are overcome, scWGS represents a promising avenue to 406 
explore clonal dynamics. However, the cost for sufficient whole genome coverage in bulk 407 
and scWGS currently remains a major barrier for routine adoption. 408 
 409 
Following cell therapy treatments, scWGS can be used to assess mutation profiles at the 410 
single cell level for highly heterogeneous tumors during the follow-up stage. This information 411 
would be particularly helpful in determining why certain patients experience disease relapse, 412 
allowing for the identification of specific clones that are either highly susceptible or resistant 413 
to CAR T cell cytotoxicity. Additionally, building a more comprehensive understanding of 414 
tumor cell clonal dynamics will be key to dissecting out subpopulations that could then be 415 
profiled with the aim of identifying new TSAs. This type of approach can be applied to any 416 
group of diseases where complex mutation profiles are expected to impact the effectiveness 417 
of treatment.   418 
 419 
Immune receptor repertoire analysis facilitates the interrogation of clonal dynamics of the 420 
adaptive immune response and thus provides a crucial tool for immunotherapy (186). In 421 
particular, the development of VDJ-sequencing and single-cell T cell receptor (TCR) 422 
sequencing enabled robust profiling of the output of VDJ recombination, using targeted PCR 423 
and NGS (187,188). A multitude of studies outlined the efficacy of TCR sequencing for 424 
immune cell profiling in cancer patients to help stratify patient cohorts for immunotherapy, 425 
identify the T cell repertoire in the tumour microenvironment and determine the response to 426 
PD-1 therapy (189–191). Intriguingly, computational tools have also been developed to 427 
enable retrospective VDJ profiling from global single cell sequencing data, thus negating the 428 
need for separate immune receptor profiling (192). Nevertheless, limited availability of 429 
patient tissue samples and peripheral blood can prevent identification of rare clones and 430 
sequential PCR amplification increases risk of amplification biases (193). 431 
 432 
Epigenome. The epigenome plays a crucial role in determining cell identity and function with 433 
chromatin organization playing a critical role in modulating gene expression and other 434 
regulatory functions (194). Chromatin accessibility is governed by the core epigenetic 435 
mechanisms of DNA methylation and post-translational modifications of histones (195). 436 
Thus, being able to screen DNA methylation, chromatin accessibility and histone 437 
modification at single cell resolution can provide crucial insight into tissue heterogeneity.  438 
 439 
To identify open chromatin regions and characterize regulatory elements, Buenrostro and 440 
colleagues pioneered the assay for transposase-accessible chromatin using sequencing 441 
(ATAC-seq) protocol (196). In brief, this protocol leveraged the previously described 442 
hyperactive Tn5 transposase to simultaneously fragment open chromatin regions and 443 
introduce sequencing adaptors for subsequent library synthesis (166,196,197). While the 444 
original ATAC-seq protocol required 500-50,000 cells, the adaptation to inspect single cells 445 
soon followed. Buenrostro et al. used the Fluidigm microfluidic platform, allowing single cell 446 




inception, others have developed approaches to increase the throughput of scATAC-seq to 448 
tens, or even hundreds of thousands of cells (198,199). Illustrating its power, Sapathy et al. 449 
generated scATAC-seq profiles for over 60,000 primary human bone marrow and peripheral 450 
blood mononuclear cells (PBMC) (198). Here, the authors identified cell-type specific cis-451 
elements, key transcription factor (TF) activity across a broad range of hematopoietic 452 
populations and gene activity, using aggregate accessibility of multiple cis-elements for a 453 
single gene. Most intriguingly, such high density of single cell clusters permits the inference 454 
of complex differentiation trajectories. Using the well-characterized development of B cells, 455 
the authors were able to reconstruct the differentiation pathway, characterize cis-elements of 456 
each cell type, and identify active TF programs along the entire differentiation trajectory. 457 
Unsurprisingly, scATAC-seq enabled a previously unseen insight into tumor evolution, such 458 
as the role of naïve cell types in driving tumorigenesis (198,200,201).  459 
 460 
DNA methylation of cytosine residues (5mC) plays a crucial role in epigenetic regulation, 461 
including the modulation of cis-regulatory elements (202). In particular, DNA methylation has 462 
been implicated in gene silencing to regulate transcriptional activity during development and 463 
altering transcription factor binding (203,204). The development of bisulphite sequencing 464 
(BS-seq) enabled unbiased, genome-wide inspection of the DNA methylome (205). To 465 
enable BS-seq at single cell resolution (scBS-seq), pioneering work by Smallwood et al. 466 
adapted the existing post-bisulfite adapter tagging protocol to derive quantitative DNA 467 
methylation signatures at up to 50% of CpG islands (206–208). Smallwood et al. and others 468 
have extensively applied scBS-seq to interrogate mouse gastrulation, human implantation, 469 
embryonic stem cells and alternative splicing at single cell resolution (207,209–211).  470 
 471 
The clinically-relevant utility of scATAC-seq in building a comprehensive understanding of 472 
the tumor microenvironment has been clearly shown by Sapathy et al. (212) where 473 
chromatin accessibility was mapped for more than 37,000 cells from five sets of serial basal 474 
cell carcinoma tumor biopsies. Pre- and post-PD-1 inhibitor treated samples were profiled 475 
and cell types formed clearly defined clusters, with tumor cells and non-tumor populations 476 
clustering away from one another (212). One major strength of this method is the ability to 477 
assess chromatin accessibility at specific cis-elements in disease-associated loci across 478 
multiple cell types. This allows for the annotation of tumor-specific, immune cell population-479 
specific or stromal-cell specific active cis-elements. Aside from describing active and inactive 480 
chromosomal regions for various cell populations, scATAC-seq can also be combined with 481 
individual lentiviral integration site mapping, enabling researchers to examine where these 482 
sites fall in relation to open chromosome regions (213). This type of information can be 483 
useful in assessing whether integration of viral components in or near specific genes can be 484 
connected to robust expansion or in vivo persistence of CAR T cells (213). The same 485 
approaches could be used to assess how viral integration in certain chromosomal regions 486 
affects outcomes in gene therapy. These studies clearly demonstrate how this approach 487 
permits comparison of diverse cell populations that directly impact both the disease 488 
microenvironment and response to treatment.  489 
 490 
In some diseases, therapeutic benefits may be attained through the de-repression of 491 
epigenetically silenced genes. One such example involves triggering the expression of fetal 492 
gamma-globin (HbF) to correct the pathophysiological defects associated with SCD 493 
(80,214). One preclinical study aiming to identify a novel treatment for Fragile X syndrome 494 




region, leading to increased FMR1 expression (215). Newly developed CRISPR/Cas9-496 
mediated demethylation and methylation tools allow for the manipulation of the methylome 497 
(216–219). In order for these strategies to be developed into viable treatments, techniques 498 
such as scBS-seq will be required to ensure that targeting is specific and that it does not 499 
lead to outgrowth of modified cells. 500 
 501 
Recent evidence suggests that changes in CAR T cell global methylation status may have 502 
some bearing on treatment efficacy. One study found enhanced proliferation and persistence 503 
of a dominant CAR T clone with biallelic disruption of the TET2 gene, which encodes a 504 
demethylating enzyme (220). Another study provided evidence that decitabine treatment-505 
mediated epigenetic reprogramming of CAR T cells led to enhanced cytotoxicity and 506 
persistence (221). scBS-seq profiling of CAR T cells in a variety of patient samples has the 507 
potential to identify novel mechanisms that play a role in determining overall treatment 508 
response. 509 
 510 
Single-cell epigenomic screening, such as scATAC-seq and scBS-seq, can provide crucial 511 
insights into the disease microenvironment, tumor-infiltrating lymphocytes or epigenetic 512 
disruption in disease. However, the rapid technological advances in single cell epigenomics 513 
posed a new challenge – the computational analysis of large data volumes. In addition, high 514 
background noise levels, low sequencing depth and limited capture rates of single-cell 515 
epigenetic screens restricts the analytical scope of pipelines developed for bulk sequencing 516 
protocols (222). Hence, current analytical strategies leverage a pseudo-bulk approach. First, 517 
single cells are aggregated for peak calling, then individuals cells are inspected for identified 518 
pseudo-bulk peaks (223). More recently, comprehensive tools have been developed to 519 
integrate dimensionality reduction, peak calling, identification of variable peaks, motif 520 
analysis, prediction of gene association and differentiation trajectories into single pipelines 521 
(224,225).  522 
 523 
Transcriptome. Single-cell RNA sequencing (scRNA-seq) is arguably the most widely 524 
applied and established single-cell molecular screening platform. Consequently, a multitude 525 
of novel scRNA-seq protocols and adaptations have been developed (extensively reviewed 526 
elsewhere: (226,227)). Amongst these, two major groups have emerged, primarily differing 527 
in sequence coverage to either profile full-length transcripts or sequence the 3’ or 5’ ends of 528 
captured transcripts. Picelli and colleagues pioneered Smart-seq2 for full-length 529 
transcriptomic profiling of hundreds of cells (38). Alternatively, platforms for 3’ mRNA 530 
profiling, such as Drop-seq (37) and more recently Chromium (10X Genomics) (228), utilise 531 
droplet-based microfluidic devices and unique molecular identifiers for massively high-532 
throughput single-cell screens. This technological advance allowed profiling of tens or 533 
hundreds of thousands of cells at significantly reduced sequencing costs per cell compared 534 
to full-length profiling protocols. These high throughput techniques enable deep molecular 535 
profiling of complex tissues and are particularly beneficial for the identification of rare cell 536 
types. In contrast, full-length profiling protocols are not compatible with droplet-based 537 
approaches, thus reducing the throughput by 10- to 1000-fold at increased sequencing cost 538 
per cell (227). However, Smart-seq2 provides deeper sequencing coverage, resulting in the 539 
detection of a larger number of genes with fewer sequencing dropouts (229,230), allowing 540 
much more robust conclusions about transcript co-expression in single cells. Increased 541 
sequencing depth also provides increased detection of low-abundance transcripts. Perhaps 542 




and novel transcripts (227). Taken together, both sequencing platforms provide a diverse 544 
toolbox to cover a broad range of biological questions, but it is imperative to choose the right 545 
tool for the biological question being addressed. 546 
 547 
Multiple studies have demonstrated the utility of scRNA-seq in describing cell-cell 548 
interactions, discovering unique disease-associated cell populations, identifying minimal 549 
residual disease following treatment and even distinguishing host- versus donor-derived 550 
cells following transplantation (228,231–234). These types of applications can easily be used 551 
to address a number of currently unanswered questions relating to all phases of the gene 552 
therapy process (Table 1). As a lower-cost alternative to WGS, scRNA-seq can be used to 553 
identify single nucleotide variants (SNVs) and splice variants in gene corrected cells 554 
(227,235). Given that scRNA-seq is also particularly powerful in separating heterogeneous 555 
groups of cells (231), these datasets can be very useful in identifying genes and pathways 556 
relevant to the function of abnormal cell types that participate in the establishment of 557 
diseases such as diabetes (236)(237). In turn, this information can be employed to develop 558 
new therapeutic avenues. 559 
 560 
Similar to its applications in gene therapy, scRNA-seq can also be used to dissect basic 561 
biological processes such as T cell development (238), aspects of which may inform the 562 
optimization of CAR T cell therapies. As discussed above, a number of studies profiling anti-563 
CD19 CAR T cell populations before and after infusion into patients have been able to draw 564 
clinically relevant conclusions about transcriptional profiles that mark CAR T cells associated 565 
with both good and poor clinical outcomes (238,239). scRNA-seq studies can also be used 566 
to examine interactions occurring within the tumor microenvironment between various 567 
endogenous immune cell types and CAR T cells (240).  568 
 569 
Proteome. The eukaryotic proteome provides the greatest molecular complexity within the 570 
genotype-phenotype paradigm. With the addition of post-translational modification, the 571 
number of functionally distinct proteins considerably exceeds the ~20,000 identified protein-572 
coding genes (241). In addition to the complexity of the proteome, the absence of protein 573 
amplification tools has limited our ability to perform unbiased proteomic screens. Traditional 574 
hypothesis-driven approaches, such as high-resolution microscopy, flow cytometry and 575 
immunohistochemistry, have enabled protein quantification at single cell resolution (242); 576 
however, these techniques are limited by the number of screened proteins, cell throughput, 577 
and the need to know the target a priori. These limitations are partly addressed by mass 578 
cytometry, a high-throughput quantitative screen for up to 60 proteins using currently 579 
available protocols and a theoretical capacity of up to 120 proteins (243). The principle of 580 
mass cytometry, or cytometry by time-of-flight (CyTOF), was based on the core concept of 581 
covalent conjugation of multiple individual antibodies with unique heavy metal reporter 582 
isotopes with district ion masses (244). In brief, single cells, labelled with a complex set of 583 
reporter-conjugated antibodies, are vaporised by inductively coupled plasma to release 584 
reporter ions for analysis by time-of-flight mass spectrometry (245–247). Unique ion mass 585 
sizes permit deconvolution and ultimately the quantitative comparison of labelled proteins on 586 
individual cells.  587 
 588 
Pioneering work by Palii and colleagues utilised CyTOF to determine the role of lineage-589 
specific transcription factors (LS-TF) in hematopoietic lineage specification (248). By 590 




multipotent progenitor populations undergo gradual LS-TF changes to commit to single 592 
lineages at the single cell level. Furthermore, CyTOF has been widely applied in immune cell 593 
profiling, biomarker discovery and treatment response studies (243,249,250). Such findings 594 
demonstrate the power of single-cell approaches to decipher complex molecular 595 
interactions, which would otherwise be masked in bulk studies.  596 
 597 
As previously mentioned, one of the potential risks of virus-based gene therapy is the 598 
development of an immune response targeting the delivery vehicle. A major strength of 599 
CyTOF is its ability to profile multiple cell types simultaneously, allowing researchers to 600 
create snapshots of proteins being expressed both on the cell surface and intracellularly 601 
(251,252). With the aim of determining whether healthy donor PBMCs were reactive to viral 602 
vector components used in many gene therapy clinical trials, Kuranda et al. simultaneously 603 
profiled cytokine secretion, immune cell activation, and T cell exhaustion using CyTOF (253). 604 
Different immune cell responses were observed, some of which correlated with whether or 605 
not the donor had previously been exposed to the virus originally used to develop clinical 606 
viral vectors. These findings indicate that it may be possible to predict which patients will go 607 
on to develop vector immunogenicity (253). This type of approach can also be applied to the 608 
monitoring of immune cell interactions following CAR T cell infusion.  609 
 610 
While CyTOF was originally developed for the screening of suspension cells, Giesen et al. 611 
pioneered imaging mass cytometry (IMC) to introduce spatially resolved mass cytometry of 612 
~30 proteins (254). Giesen and colleagues elegantly combined traditional 613 
immunohistochemistry with laser ablation and mass cytometry, thus enabling mass 614 
cytometric screening across tissue sections with subcellular resolution. Two concurrent 615 
studies utilised IMC for screening islets and the immune cell compartment of type 1 diabetes 616 
patients at single-cell resolution (255,256). The authors demonstrated the alterations in islet 617 
topology during disease progression and the role of T lymphocytes in β-cell destruction. 618 
 619 
As outlined above, high-throughput single-cell phenotyping plays a crucial role in gene and 620 
cell therapy. CyTOF and other flow cytometry-based technologies, such as full spectrum flow 621 
cytometry (FSFC) and Chipcytometry, enable phenotyping of dozens of distinct cell types 622 
(257,258). In brief, Chipcytometry utilises microfluidics to enable iterative inspection of cell 623 
surface markers, while FSFC relies on full spectral acquisition to enable parallel screening of 624 
dozens of cell surface markers (257,258). Near limitless throughput and high capture 625 
efficiency paired with the ability to distinguish rare cell populations provides a powerful tool 626 
for immunophenotyping. Indeed, FSFC has been successfully applied to identify therapy-627 
mediated alterations in peripheral blood mononucleocyte profiles of head and neck 628 
squamous cell carcinoma patients (259).  629 
 630 
Despite these advances, the high cell throughput and complexity of acquired CyTOF data 631 
provides a significant computational challenge and remains a key focus area for technical 632 
development (comprehensively reviewed elsewhere: (260)). Recent technological advances 633 
in mass spectrometry and upstream sample processing have also raised the prospect of 634 
unbiased proteomic screens. Separate work by the Slavov and Mann groups have shown a 635 
capacity to capture ~3000 and ~800 proteins per cell, respectively (261–263). At present, 636 
however, the technology is prohibitive for routine application and will require substantial 637 





Multimodal sequencing of complex tissues 640 
 641 
The development of single-cell uni-modal sequencing platforms to independently interrogate 642 
the genome, epigenome, transcriptome or proteome has raised the prospect of screening 643 
multiple components simultaneously (multimodal profiling). 644 
 645 
Numerous approaches for separating genomic DNA and mRNA from the same single cell 646 
have been proposed (various approaches extensively reviewed elsewhere: (165)). Amongst 647 
these, the elegant G&T-seq protocol, pioneered by Macaulay et al., separates mRNA from 648 
genomic DNA by using magnetic beads and biotinylated oligo(dT) primers against poly-A 649 
tails of mRNA molecules (Figure 3 and Table 2) (48). The full-length transcript profiling in 650 
G&T-seq assays provides a powerful tool for identifying alternatively spliced transcripts, 651 
fusion transcripts and expression of single nucleotide variants (SNVs) (264). The ability to 652 
associate such information with DNA copy number and structural variants at the single cell 653 
level allows unprecedented insight into the relationship of the genotype and its gene 654 
expression profiles. Nevertheless, manual separation of DNA and mRNA during the G&T-655 
seq protocol increases sample handling, thereby limiting the throughput to hundreds of cells 656 
(264) which is further compounded by the high sequencing costs to ensure sufficient 657 
genome coverage.  658 
 659 
Whole genome sequencing (WGS) approaches provide a crucial tool for characterizing 660 
genomic abnormalities in primary tumors (265). Zhu et al. recently applied G&T-seq to a 661 
subset of lymphovascular invasive cells, isolated from a breast cancer patient (266), 662 
describing the relationship between RNA and CNV clones and outlining multiple functionally 663 
distinct clones and their role in metastatic dynamics. This illustrates the power of G&T-seq to 664 
uniquely integrate genomic abnormalities with transcriptional consequences, potentially of 665 
substantial utility in deciphering tumor heterogeneity and intra-tumoral clonal dynamics post 666 
CAR T therapy. 667 
 668 
Existing epigenetic single-cell assays have also been adapted to enable multimodal 669 
approaches (Figure 3 and Table 2). For example, Angermueller et al. adapted the existing 670 
principles of G&T-seq by introducing a bisulfite treatment step which allowed DNA 671 
methylation profiles and gene expression to be obtained from the same cell (scM&T-seq) 672 
(46). A more recent adaptation to the scM&T-seq protocol introduced chromatin accessibility 673 
as the third dimension for simultaneous single-cell nucleosome, methylation and 674 
transcription sequencing (scNMT-seq) (267). Here, a methyltransferase is used to label 675 
accessible DNA prior to scBS-seq. Such labelling permits downstream computational 676 
deconvolution of DNA methylation and chromatin accessibility profiles (268). To date, 677 
scM&T-seq and scNMT-seq have provided intriguing insight into stem cell biology and 678 
mouse gastrulation. For instance, pioneering work by Argelaguet and colleagues described 679 
the role of epigenetic priming at lineage-specific enhancers during lineage commitment 680 
(209). A second pioneering study revealed that changes in DNA methylation drive increasing 681 
transcriptional heterogeneity during stem cell ageing (269). These studies demonstrate the 682 
impact of a multi-modal scNMT-seq for characterising the role of the epigenome in complex 683 
tissues and biological processes, including the underlying cellular heterogeneity.  684 
 685 
Taking into account the role of DNA methylation in driving autoimmune defects, age-related 686 




for uncovering novel therapeutic avenues. These principles can also be applied for 688 
assessing the extent to which normal tissue function can be restored following corrective 689 
gene therapies. Similarly, multimodal epigenetic and gene expression profiling can provide a 690 
valuable tool for characterizing the tumor microenvironment and its interaction with CAR T 691 
cells to increase therapeutic efficacy. However, the relatively low-throughput of scNMT-seq 692 
can limit the coverage of large, complex tissues. 693 
 694 
To determine the impact of cis- and trans-regulatory elements on gene expression profiles, 695 
collecting chromatin accessibility and gene expression profiles from the same cell are of 696 
paramount importance. Cao et al. pioneered sci-CAR to simultaneously perform nuclear 697 
scRNA-seq and scATAC-seq (272) by adapting previously established principles of single-698 
cell combinatorial indexing to barcode mRNA and open chromatin regions from single nuclei 699 
extracts. Shortly thereafter, Chen and colleagues developed SNARE-seq for performing 700 
simultaneous gene expression and chromatin accessibility profiling (273). In contrast to sci-701 
CAR, SNARE-seq utilized the high-throughput Drop-seq platform to incorporate single nuclei 702 
and adapter-coated beads. Upon nuclei lysis within each droplet, released nuclear RNA and 703 
chromatin fragments bind to the uniquely barcoded beads allowing connectivity of ATAC-seq 704 
and RNA-seq profiles of individual cells. Furthermore, SNARE-seq enabled significantly 705 
improved capture of chromatin fragments and improved the transcript sequencing depth 706 
(273). That said, the potential of SNARE-seq is partially restricted by the complexity of 707 
downstream data analysis and this prompted the development of integrated analysis 708 
pipelines, such as Signac (224) and the Chromium Single-Cell Multiome ATAC + Gene 709 
Expression platform. The simplification of the sample preparation process and analysis 710 
pipelines will be required to facilitate the wider adoption of multi-modal epigenetic and gene 711 
expression screening.  712 
 713 
A vast array of computational tools has been developed for the analysis of unimodal single 714 
cell data. For instance, advances in dimensionality reduction, clustering and algorithms for 715 
identifying marker genes, constructing lineage trajectories and batch correction contributed 716 
greatly to today’s widespread access to scRNA-seq analysis tools (165). The assembly and 717 
curation of key tools into unified analysis pipelines, such as Seurat, SCRAN or SCANPY, 718 
has enabled bench-trained scientists to independently analyse scRNA-seq data (274–277). 719 
Datasets from multimodal analysis with distinct cellular dimensions inherently do not share 720 
common features (278), making data integration across distinct modalities from the same 721 
cell a profound and novel computational challenge. To integrate multiple modalities collected 722 
from the same cells into a single reference describing cell identities, Hao et al developed a 723 
Weighted Nearest Neighbour (WNN) framework (279). In brief, WNN utilises nearest 724 
neighbour analysis and computes modality weights to derive a single landscape, reflecting 725 
the similarities of all modalities. The increased adoption of single-cell multimodal screens 726 
provides another computational challenge - the integration of multimodal data across distinct 727 
experiments, platforms and batches. While multiple strategies to integrate and batch-correct 728 
unimodal scRNA-seq datasets have been proposed (276,280), their applicability to 729 
multimodal datasets is limited. To overcome this limitation, Stuart and colleagues adapted 730 
canonical correlation analysis and L2 normalisation to derive anchors for data integration 731 
(281). To enable integration in a variety of experimental settings, several anchoring methods 732 
have been proposed (reviewed in (282)). Nevertheless, the rapidly expanding landscape of 733 




approaches and recent developments in multimodal data analysis are expansively reviewed 735 
elsewhere (165,278). 736 
 737 
Overall, technological advances have resulted in an unprecedented proliferation of novel 738 
single-cell molecular assays. Intriguingly, the capability of incorporating such approaches to 739 
acquire multiple elements from single cells has allowed the interrogation of the direct 740 
relationship of multiple molecular dimensions. Such extensive single-cell profiling is 741 
particularly beneficial for application in future cell therapies where the interrogation of tumor 742 
infiltrating lymphocytes and tumor microenvironments will provide a crucial component for 743 
target discovery and monitoring of therapeutic efficacy. Due to the heterogeneous nature 744 
and shifting clonal dynamics of malignant tissues, single-cell approaches are of paramount 745 
importance for the development of effective cell therapies.  746 
 747 
Multimodal single-cell approaches integrating functional and molecular data 748 
 749 
Simultaneously acquiring functional and molecular readouts from the same cells have 750 
historically represented an experimental challenge, as omics profiling tools typically result in 751 
destruction of the target cell. This is particularly challenging when the functional state of a 752 
cell is determined by a retrospective assay, thereby making its prospective isolation and 753 
molecular characterization impossible. Hence, most technical developments that combine 754 
functional and molecular multimodal approaches have focused on capturing cellular function 755 
prior to a destructive single-cell assay.  756 
 757 
Transcriptome and the cell surface proteome. One of the first applications of multimodal 758 
omics technologies arose from the desire to connect cell surface phenotypes with gene 759 
expression profiles. Several well-characterized biological systems, particularly immune cell 760 
subtypes and hematopoiesis, have benefited from in-depth characterization of cell surface 761 
markers for a variety of functionally distinct cellular populations (283). As a result, 762 
quantitative phenotypic information of selected cell surface markers can permit inference of 763 
cellular function. Fluorescence-activated cell sorting (FACS) in combination with index 764 
sorting allows simultaneous recording of cell surface protein levels prior to deposition in lysis 765 
buffer for downstream destructive molecular assay, such as the Smart-seq2 protocol for 766 
gene expression profiling (38). The application of such approaches has allowed the linkage 767 
of stem cell function with global molecular profile for the first time and provided numerous 768 
insights into our understanding of transcriptional heterogeneity throughout hematopoiesis 769 
(44,283–285). 770 
 771 
Strategies involving index sorting and downstream scRNA-seq are particularly powerful 772 
when combined with functional outcome analyses. Wilson et al. and others have shown how 773 
these methods can be applied to understanding the heterogeneity inherent to many normal 774 
tissues and identifying features that differentiate normal and disease-causing cell types 775 
(285–291). These methods would be particularly useful in linking T cell function to distinct 776 
gene expression profiles, allowing for the identification of subpopulations of cells that are 777 
associated with specific clinical outcomes.  778 
 779 
Nevertheless, isolation strategies of functional cell types frequently do not achieve 780 
homogeneity and contaminating cells cannot be fully excluded from destructive molecular 781 




functional cells from contaminants, meaning that cellular heterogeneity is often the first to be 783 
identified (i.e., they drop out of the assay and do not generate a confusing data point) (292). 784 
Furthermore, cell isolation by FACS requires prior knowledge of distinct cell types, thereby 785 
precluding the discovery of novel cell types. In addition, index-sorting FACS-based 786 
approaches are not compatible with droplet-based high-throughput sequencing platforms. To 787 
overcome these limitations, Stoeckius et al. pioneered CITE-seq (cellular indexing of 788 
transcriptomes and epitopes by sequencing, Figure 3 and Table 2) (45). Here, antibodies 789 
against cell surface proteins of interest are labelled using unique oligonucleotide barcodes. 790 
Antibody-labelled cells are subjected to the Drop-seq protocol, encapsulating single cells in 791 
droplets containing beads to introduce unique cellular barcodes to mRNA and the antibody-792 
derived tags (ADTs). Subsequently, ADT counts are used to quantify antibody-bound cell 793 
surface proteins and provide a link to the corresponding single-cell gene expression profiles. 794 
Consistent surface proteome quantification and resolution were achieved compared to 795 
traditional flow cytometry approaches, while providing a theoretically unlimited scope for 796 
antibody multiplexing (45).  797 
 798 
The application of CITE-seq in tumor microenvironment biology has been noted previously 799 
(293,294).  Praktiknjo et al. screened healthy and tumor-bearing mouse salivary glands, 800 
including the immune compartment of the tissue (294). By performing CITE-seq, the authors 801 
were able to construct a comprehensive gene expression atlas and simultaneously recorded 802 
a comprehensive set of 63 immune-specific cell surface proteins. Most notably, they derived 803 
a comprehensive cell atlas of the tumor microenvironment, using gene expression profiles 804 
and quantification of cell surface proteins, underscoring the utility of CITE-seq in the 805 
discovery of novel tumor-specific cell surface antigens for cell therapy. By linking surface 806 
protein quantification with gene expression profiling at single cell resolution, CITE-seq can 807 
identify novel antigens associated with specific clones within heterogeneous cancer tissues, 808 
ultimately raising the prospect of a broader spectrum of effective cell therapies. The efficacy 809 
of multimodal single-cell screens, such as CITE-seq has been particularly evident throughout 810 
the scientific response to the COVID-19 outbreak. Combined efforts to screen >780,000 811 
single PBMCs from COVID-19 patients and healthy donors using CITE-seq revealed the 812 
immune response to COVID-19 infections and its role in disease pathology (295). Such 813 
studies provide a prominent example how single-cell multiomics can provide rapid insight 814 
into previously unknown diseases and help inform the development of effective therapeutics. 815 
 816 
Perturbation screens. Large-scale perturbation screens have previously provided 817 
unprecedented insights into gene functions and their role in complex biological mechanisms 818 
(296). The advent of CRISPR/Cas9 has revolutionized our ability to conduct high-throughput 819 
perturbation screening and multiple groups have now developed multimodal single-cell 820 
perturbation screens, combining CRISPR technology with scRNA-seq (47,297–300). In 821 
Perturb-seq (Figure 3 and Table 2), a pool of barcoded single-guide RNAs (sgRNAs) is 822 
constructed against a set of 24 transcription factors and transduced cells are subjected to 823 
high-throughput droplet-based sequencing, whereby unique cell barcodes are also 824 
introduced. The dual barcoding approach allows connection of single-cell gene expression 825 
profiles with a respective perturbation. Such single-cell CRISPR screens and their ability to 826 
interrogate transcriptional consequences of perturbations provided a novel method to assess 827 
the functional effectors of complex biological mechanism and tissues (300,301). Of note, Jin 828 
et al. demonstrated the application of Perturb-seq in an in vivo setting (302). To interrogate 829 




pool against risk genes to the forebrain of a developing embryo in utero. The progeny of 831 
perturbed cells was then collected at P7 for downstream scRNA-seq analysis, providing key 832 
insights into the molecular mechanisms of neocortical cell types.  833 
 834 
Perturb-seq can be very useful in trying to understand larger pathways that integrate multiple 835 
signals. For example, Adamson et al. used Perturb-seq to understand how activation of the 836 
unfolded protein response (UPR) differed between individual cells (300). This type of data 837 
has the potential to disentangle larger signaling networks, all of which is important for 838 
understanding complex processes such as immune responses.  839 
 840 
Despite the demonstrated efficacy, application of Perturb-seq is limited by the sequencing 841 
depth of high-throughput approaches. Acquired data is subject to significant background 842 
noise and low-abundant transcripts are frequently missed (47,297). Furthermore, the 843 
multiplicity problem of combining multiplexed perturbations with single-cell gene expression 844 
profiles poses a computational challenge. Schraivogel proposed an intriguing adaptation, 845 
termed targeted Perturb-seq (TAP-seq) (303). By performing targeted amplification of a 846 
selected set of genes prior to sequencing, the cost and analytical complexity could be 847 
significantly reduced. This approach provides a powerful tool for screening cellular pathways 848 
with defined genetic biomarkers. In the context of cell therapy, TAP-seq could thus provide a 849 
cost-effective tool for identifying underlying molecular mechanisms of immune cell evasion of 850 
CAR T therapy.  851 
 852 
There have been a wide variety of additional approaches to integrate single-cell perturbation 853 
screens with the surface proteome of the same cell. Most notably, Mimitou et al. proposed 854 
ECCITE-seq (304) and Frangieh et al. described Perturb-CITE-seq (305). In brief, Mimitou et 855 
al., adapted the existing CITE-seq protocol by introducing addition oligonucleotides against 856 
unique sgRNA identifiers to cellular barcoding beads. Thus, sgRNA, transcripts, antibody-857 
oligonucleotides and up to 2 other parameters can be recorded for individual cells (304). 858 
More recently, Frangieh et al. proposed Perturb-CITE-seq to provide a scalable solution for 859 
Perturb-seq with simultaneous screening of cell surface proteins (305). Here, the authors 860 
demonstrated the benefits of Perturb-CITE-seq by identifying molecular pathways driving 861 
immune evasion of a melanoma cell line against primary tumor infiltrating lymphocytes (305). 862 
Overall, the ability to connect gene expression profiles and the cell surface proteome from 863 
single cells under perturbation provides a comprehensive characterisation of complex 864 
molecular systems. As demonstrated by Frangieh et al., such technologies can help identify 865 
and characterize immune evasion drivers and ultimately reveal novel targets that might lead 866 
to enhanced therapeutic potency of immunotherapies.  867 
 868 
Clonal tracking and lineage tracing. Recent work by Lee-Six et al. outlined the application 869 
of whole genome sequencing (WGS) approaches to establish the clonal dynamics of human 870 
HSPCs (185). The authors isolated single HSPCs from a healthy donor and were able to 871 
retrospectively reconstruct the phylogenetic tree of single cell-derived colonies, based on a 872 
broad set of shared or unique acquired somatic mutations. By simultaneously screening 873 
mature cells isolated from peripheral blood samples of the same individual, Lee-Six et al. 874 
were able to infer the progeny and extended relatedness of stem cell clones. Using this 875 
approach in a 59 year old human, the authors could map all the way back to the most recent 876 




cell compartment and confirmed hematopoietic activity of a large number of diverse HSC 878 
clones estimated to be between 50,000 and 200,000 actively contributing HSCs (175,185).  879 
 880 
This technique could be powerfully applied to gain insight into the clonal dynamics of HSCs 881 
used in gene therapy. Careful patient monitoring must be undertaken to ensure therapeutic 882 
efficacy and restoration of normal tissue function. As multipotent cells provide the most 883 
common target for gene therapies, gene corrections can significantly impact the clonal 884 
dynamics of the target tissue. Intriguingly, previous efforts to track therapeutic efficacy of 885 
corrective therapies large depended on monitoring progeny cells, their homeostatic function 886 
and particularly the proportion of target cells expressing the desired gene edit (306,307). 887 
However, such approaches do not provide sufficient resolution to fully characterize clonal 888 
dynamics of corrected cell types and their impact on homeostatic tissue function. WGS of 889 
single cell-derived colonies allows to monitor naturally occurring somatic mutations in 890 
multipotent cells and their progeny to establish their relationship and infer clonal dynamics of 891 
single cells (175). When applied to a pool of edited cell and mature cell progeny post-gene 892 
therapy, such approaches can provide a direct insight into therapeutic efficacy and long-term 893 
tissue health.  894 
 895 
In contrast, upfront labelling of target cells followed by temporal tracking of their progeny can 896 
reveal patterns of clonal evolution. Here, the advent of routine and cost-effective sequencing 897 
also revolutionised lineage tracing, providing a compelling alternative to traditional imaging-898 
based approaches. In the context of diabetes, lineage tracing has been used to track the 899 
various cell types which originate from pancreatic progenitor cell populations (308–310) and 900 
identify cell types that are able to transdifferentiate into insulin-secreting cells (311–313). 901 
High-throughput screening at single cell resolution and integration into multimodal 902 
approaches greatly expand the scope of lineage tracing (314). While fluorescent tags limit 903 
the capacity of parallel barcoding, DNA sequence complexity provides a scalable barcoding 904 
approach. In principle, unique DNA barcodes are first introduced into a large population of 905 
target cells. Subsequently, amplification of the unique set of DNA barcodes in cell progeny 906 
can be used to compute lineage phylogenies (315,316). A prominent barcoding approach 907 
relies on CRISPR/Cas9-mediated dynamic lineage tracing. Here, CRISPR/Cas9-mediated 908 
double-stranded breaks are introduced at defined genomic loci (317). The resulting 909 
insertions and deletions (indels) create unique cellular barcodes, which evolve over time. By 910 
sequencing such regions, the mutational patterns can be used to establish phylogeny and 911 
clonal evolution. Multiple groups have independently pioneered such CRISPR/Cas9-based 912 
lineage tracing approaches, which predominantly differentiate in the number of loci used to 913 
store lineage barcodes (318–324). Of note, using genome editing of synthetic target arrays 914 
for lineage tracing (GESTALT), McKenna et al. were able to trace and reconstruct early 915 
developmental pathways in a whole organism.  916 
 917 
Dynamic lineage tracing protocols outlined above have been integrated in multimodal 918 
screens to link cellular progeny to their respective gene expression profiles, including single-919 
cell GESTALT (scGESTALT), linear tracing by nuclease-activated editing of ubiquitous 920 
sequences (LINNAEUS) and ScarTrace (Figure 3 and Table 2) (318,319,325). Raj et al. 921 
integrated the underlying principles of GESTALT with scRNA-seq to simultaneously acquire 922 
lineage information and gene expression profiles of the same cell (325). Instead of targeted 923 
sequencing of genomic DNA, scGESTALT relies on sequencing of expressed transgenes, 924 




expression thus provides cell type information, otherwise lost in previous lineage tracing 926 
protocols. Intriguingly, the LINNAEUS and ScarTrace protocols introduce barcodes in 927 
fluorescent transgenes to allow monitoring of successful integration of cellular barcodes. 928 
Thus, providing a crucial quality control mechanism prior to performing computational- and 929 
capital-intense sequencing (318,319).  930 
 931 
While prospective lineage tracing is not possible in humans, the use of these techniques in 932 
preclinical studies has the potential to unlock cellular relationships that are relevant to 933 
understanding cell origins in normal and diseased tissues. Furthermore, lineage tracing may 934 
also be used to link immature immune cell types to their immunologically active terminally 935 
differentiated counterparts. This could feed into refinements of CAR T cell production 936 
protocols for example, allowing for the selection of specific populations with maximal effector 937 
function (326). 938 
 939 
Nevertheless, these multimodal lineage tracing technologies are currently in their infancy 940 
and a variety of experimental and computational limitations require attention. Shallow 941 
sequencing depth of high-throughput approaches can prevent barcode detection and 942 
CRISPR/Cas9-induced cell toxicity has recently been described, thus potentially disrupt the 943 
effective construction of phylogeny or distort separation of cell types (314,327,328). 944 
Furthermore, Spanjaard et al. noted the probability of double scarring, whereby a subset of 945 
non-homologous end joining-mediated errors have a higher probability of occurring (318). 946 
Thus, if not excluded, high-frequency scars can result in false inference of lineage 947 
relationship. To address the issue of barcode duplications and noise, Zafar et al. recently 948 
proposed a novel analytical pipeline for improved lineage tree reconstruction and integration 949 
of separate single-cell lineage tracing experiments (49). While these advances are 950 
promising, further computational innovation will be of paramount importance for the adoption 951 
of single-cell lineage tracing in gene and cell therapy developments.  952 
 953 
Introducing spatial resolution in gene and cell therapy 954 
 955 
Single-cell sequencing technologies and their multimodal integration continue to push the 956 
boundaries of understanding the mechanisms governing complex tissue organization. 957 
However, such single-cell screening protocols are largely based on removing the cells and 958 
destroying them, typically discarding any spatial information of the underlying tissue from 959 
which they were extracted. The crucial role of cellular location and spatial gene expression 960 
throughout early embryogenesis has been widely recognized (329). Similarly, cellular 961 
location in heterogeneous tumors and the surrounding tumor microenvironment are vital to 962 
cell function (330). Therefore, resolving spatial dimensions and linking these with gene 963 
expression profiles to infer gene function and cell identity can help us understand disease 964 
pathology and complex tissue function. Here, we discuss selected technological 965 
developments in spatial transcriptomics and their prospect in the development of novel cell 966 
and gene therapies (spatial omics protocols are comprehensively described elsewhere: 967 
(329,331)). 968 
 969 
The development of fluorescence in situ hybridisation (FISH) techniques first enabled the 970 
detection of DNA and RNA molecules in structurally preserved, fixed tissue sections 971 
(43,332,333). Oligonucleotides, complementary to a target nucleotide sequence, are labelled 972 




region can be observed using optical microscopy. Ultimately, the principles of FISH 974 
facilitated quantitative detection of mRNA at subcellular resolution (43,332,334). Here, the 975 
authors constructed a library, consisting of short single fluorophore-labelled oligos, against a 976 
single mRNA target to estimate the number of mRNA molecules in a single cell, screening 977 
up to 3 mRNA sequences in parallel.  978 
 979 
To enable high-throughput spatial transcriptomic screening, Lubeck et al. first established 980 
the principles of sequential FISH (seqFISH), providing a strategy with theoretically whole 981 
transcriptome coverage (335,336). In brief, multiple single fluorophore-labelled probes are 982 
used for mRNA labelling during a single hybridization round. By stripping probes and 983 
performing multiple rounds of hybridisation, the number of unique barcoding increases 984 
exponentially. Shah et al. demonstrated the efficacy of seqFISH for screening hundreds of 985 
genes at sub-cellular resolution, providing a novel insight into the spatial organisation and 986 
transcriptional heterogeneity of the mouse brain (337). The recent introduction of an 987 
additional fluorophore to sequential hybridisation allowed further scaling of seqFISH 988 
(seqFISH+) (Figure 3 and Table 2) (338). This strategy avoids optical crowding by effectively 989 
diluting mRNA molecules into separate images. The result was a robust protocol for 990 
screening 10,000 genes in spatially resolved tissues, spanning thousands of cells (338). 991 
Here, the use of confocal microscopy for the seqFISH+ protocol provides a key advantage to 992 
facilitate wider adaption. A recent study by Lohoff et al. applied seqFISH to construct 993 
spatially resolved gene expression profiles for mouse organogenesis using a computational 994 
framework for the integration of spatially-resolved gene expression maps with scRNA-seq 995 
profiles of cell types in early mouse development (339,340). In parallel, Chen et al. 996 
pioneered a multiplexed error-robust FISH (MERFISH) approach which combined error-997 
corrected barcoded probes and sequential imaging to perform a multiplexed screen of 998 
hundreds of genes (Figure 3 and Table 2) (341). Further MERFISH developments, such as 999 
the use of expansion microscopy, enabled quantification of thousands of genes in hundreds 1000 
spatially resolved cells at a detection efficiency of ~80% (342). This high capture efficiency is 1001 
a major advantage of MERFISH.  1002 
 1003 
While the methods outlined above drove innovation in spatial transcriptomics, their relative 1004 
infancy is accompanied by experimental and computational complexity, which currently 1005 
provides a barrier to wide-spread adoption. Several commercially available platforms have 1006 
been established to provide a standardised experimental framework. The Visium platform 1007 
utilised NGS for deriving spatially resolved gene expression profiles (343,344). Here, a 1008 
tissue section of interest is deposited onto a slide, coated with uniquely barcoded arrays 1009 
(barcode spacing permits 55um resolution). Following barcoding of captured mRNA 1010 
molecules, cDNA libraries are subjected to high-throughput NGS and spatial deconvolution 1011 
based on the unique barcoding. However, the current barcode spacing prevents 1012 
interrogation of neighbouring cells. Here, in situ analysis can provide a complementary 1013 
approach, allowing interrogation of a defined set of mRNA targets at spatial singe cell 1014 
resolution (345–347).  1015 
 1016 
Collectively, spatial transcriptomics technologies are currently in the developmental and 1017 
early adaption phase. As a result, several key limitations persist. For instance, the tissue-1018 
dependent optimisation and sequential hybridisation rounds require significant experimental 1019 
time, while the use of customised equipment also impacts implementation. However, 1020 




increase imaging time and data complexity, making the most prominent limiting factor the 1022 
development of robust analytical tools. To overcome the computational barrier, recent 1023 
advances aim to address key unmet needs in data analysis and its scalability (348,349).  1024 
 1025 
Despite these challenges, several major advances have already been made using spatial 1026 
transcriptomics, including studies in tumor heterogeneity and transcriptional changes in the 1027 
microenvironment. In one study, Berglund et al. constructed a comprehensive spatial map of 1028 
tumor and healthy prostate tissue biopsies from a prostate adenocarcinoma patient (330). 1029 
The authors uncovered significant transcriptional differences between the tumor core and its 1030 
periphery. Intriguingly, thorough interrogation of stromal and immune cell types, surrounding 1031 
the primary tumor, facilitated the identification of heterogeneous gene expression networks 1032 
in the tumor microenvironment (330). Spatial transcriptomics has also been applied for 1033 
mapping the localisation of Cxcl12-abundant reticular cells in the bone marrow niche and for 1034 
the characterisation of stromal cell heterogeneity in tumor microenvironments (350,351). 1035 
These and other studies demonstrate that the potential of spatial transcriptomics in 1036 
deciphering tumor architecture, heterogeneity and microenvironments has been widely 1037 
recognised. Beside its role in therapeutic discovery and disease pathology, spatially resolved 1038 
gene expression profiles can become of paramount importance for monitoring therapeutic 1039 
outcomes of cell therapies and identify evasion mechanisms in response to cell therapies. In 1040 
addition, spatial characterisation post CAR T cell therapy could provide an insight into the 1041 
impact of off-target effects on the function of proximal tissues. Similarly, spatial 1042 
transcriptomics could aid in long-term monitoring of patients undergoing corrective gene 1043 
therapies.  1044 
 1045 
Concluding remarks 1046 
 1047 
The past decade has produced an abundance of novel single-cell molecular tools, facilitating 1048 
the unbiased screening of a wide array of molecular dimensions at unprecedented 1049 
resolution. Unimodal sequencing technologies have proved particularly impactful in the first 1050 
wave of wide-scale adoption, but more approaches have been focused on combining such 1051 
techniques into multimodal screens to allow simultaneous capture of multiple molecular 1052 
dimensions from the same cell. These technologies have allowed researchers to unpick the 1053 
molecular mechanisms driving disease pathology at a scale not previously considered 1054 
possible. Tissue and disease heterogeneity, previously masked in bulk sequencing 1055 
approaches, are now routinely being explored at single cell resolution. 1056 
 1057 
Techniques such as scRNA-seq have been widely adopted due to the production of robust 1058 
experimental protocols and increasing consensus surrounding the computational 1059 
approaches for quality control and data analysis. On the other hand, multimodal screens 1060 
have not yet enjoyed similar uptake due to their reliance on high sequencing costs, 1061 
advanced integrative computational tools and technical expertise. However, just as moving 1062 
to single cells was a technical hurdle of 10 years ago, the research benefits derived from 1063 
novel multimodal screening platforms will push the limits of discovery and accelerate 1064 
technical development and method standardization. The next few years should see these 1065 
technical and computational approaches streamlined to create reproducible protocols and 1066 
standardised analytical pipelines to facilitate rapid adoption rates, as has occurred for 1067 





Concomitant with the technical challenges and need for standardization, the increased 1070 
accessibility of single-cell technologies has exponentially increased the amount of data 1071 
generated during these studies. This provides a unique opportunity to leverage the power of 1072 
these studies by integrating datasets but also makes for substantial computing and 1073 
processing challenges. Batch correction and data integration across experiments and 1074 
different sequencing platforms are areas that will require particular attention and novel 1075 
computational approaches for handling and analysing increasing amounts of data will be of 1076 
paramount importance. Ultimately, the continuous technical improvements and aggregation 1077 
of data could provide the foundation for a fully characterized reference atlas of the human 1078 
body at single cell resolution. The drive towards such a resource is evident in the recently 1079 
announced efforts to establish a common coordinate framework (CCF) for data collection 1080 
and integration (352). In line with that, initiatives such as the Human Biomolecular Atlas 1081 
Program and the CCF aim to provide a publicly available tool to help researchers map data 1082 
from diseased states onto healthy single-cell datasets and provide a reference for the entire 1083 
scientific community (352,353).  1084 
 1085 
A number of recent studies have clearly demonstrated the utility of these approaches in (1) 1086 
understanding complex biological processes such as cell fate determination and immune 1087 
response, (2) dissecting tissue and disease heterogeneity, and (3) stimulating innovative 1088 
research aimed at developing novel therapeutics (354–356). Within the next decade, it is 1089 
anticipated that an increasing number of patients across many disease types will be treated 1090 
with gene and cell therapy. Using samples obtained from these growing patient cohorts, 1091 
single-cell technologies will undoubtedly be used to answer essential questions related to 1092 
the relationships between disease-causing cells, normal or corrected cell types, tumor-1093 
targeting lymphocytes such as CAR T cells, and endogenous immune populations. For 1094 
autoimmune diseases such as type 1 diabetes where the risk of relapse is relatively high due 1095 
to immunogenicity, this level of detail will be essential to finding new ways to increase 1096 
treatment efficacy. Additionally, due to the relatively recent wider application of these 1097 
therapeutics, only a limited number of gene or cell therapy clinical trial patients have been 1098 
monitored for more than 10 years following treatment initiation (84,357–360). Depending on 1099 
the stability of edited cells and the influence of other comorbidities, detailed studies using 1100 
single-cell approaches may also become relevant during long-term follow up. As patients 1101 
enter the later decades of life, the intersection of age-related and treatment-related 1102 
abnormalities may present unique clinical challenges. Further refinements and innovations to 1103 
single-cell profiling technologies have the potential to unlock and disentangle relationships 1104 
between key drivers of disease phenotypes, leading to wider delivery of authentic 1105 
personalised medicine. 1106 
 1107 
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Figure Legends 1121 
 1122 
Figure 1. A workflow for developing and administering gene therapy. Novel gene 1123 
therapy approaches involve (A) the identification of therapeutic targets, (B) an ex vivo gene 1124 
modification step to create a transduced drug product (left) or the production of an in vivo 1125 
product (right), and (C) the infusion of these products into patients following myeloablative 1126 
conditioning.  1127 
 1128 
Figure 2. A workflow for developing and administering cell therapy. CAR T cell-based 1129 
therapies involve (A) the discovery of disease-associated antigens which can then be used 1130 
to target the cytotoxic effects of engineered CAR T cells, (B) the isolation and manipulation 1131 
of patient-derived T cell populations, (C) the infusion of these cells into patients, and (D) 1132 
downstream monitoring of disease. 1133 
 1134 
Figure 3. Single-cell multimodal platforms and their uses. A number of recently 1135 
developed technologies can be used to assess the genomic, transcriptomic, epigenomic and 1136 
proteomic landscape of a single cell. Each layer of the concentric circle represents a 1137 
different molecular dimension that can be assessed using each method (from inside to 1138 
outside: genome, epigenome, transcriptome, proteome, genetic perturbation, lineage tracing, 1139 
spatial transcriptome). Method names are indicated along the periphery. 1140 
 1141 
Figures 1142 





Table 1. Unmet needs and addressable questions in gene and cell therapy 1148 
Prior to therapy 
What is the underlying clonal diversity for complex diseases such as cancer or diabetes?  
Are there tumor-specific antigens/ mutations or cell susceptibilities that can be used to target 
various disease subclones/ abnormal cell populations? 
Can understanding the heterogeneity of diseases refined diagnosis? 
Isolation of cells to be edited/manipulated 
Gene therapy (ex vivo only) Cell therapy 
Which HSCs are mobilised and can gene 
therapy outcomes be improved if this is 
further optimised? 
Are T cells obtained from different individuals 
inherently different? What contributes to CAR T 
cell product variability?  




Gene therapy (ex vivo only) Cell therapy 
Are some HSPCs easier to transduce than 
others?  
Can we adjust this to improve treatment 
efficacy? 
Do HSPCs acquire mutations or epigenetic 
changes during ex vivo expansion and 
transduction steps? 
What makes a successful T cell product? 
Which T cell population should be used in the 
production of CAR T cells? 
How can CAR T cells be engineered to be 
more specific/minimise off-target immune cell 
activation? 
Post-treatment follow-up 
Gene therapy (ex vivo and in vivo) Cell therapy 
What are the clonal dynamics of edited cells 
over time and how does that change in 
relation to unedited cells? 
 
When transgenes or shRNAs/siRNAs are 
expressed in HSPCs, what are the 
molecular consequences of these changes 
and how do the molecular signatures of 
these cells compare to HSPCs from age-
matched healthy controls? 
 
Can low level leukemic clones be detected 
prior to overt leukemias for patients? 
 
When using in vivo approaches, what are 
the consequences of gene correction or 
transgene expression in cells that do not 
usually express the gene of interest? 
 
Can in vivo gene therapy approaches be 
designed to specifically target disease-
causing cells?  
Which factors contribute to the toxicities 
associated with CAR T cells ( cytokine-release 
syndrome (CRS), hemophagocytic 
lymphohistiocytosis (HLH) and/or macrophage 
activation syndrome (MAS))? 
 
How can on-target, off-tumor toxicities be 
minimized?   
 
Which CAR T cells survive over time and are 
some better at targeting tumor cells than 
others?  
 
Are there differences between CAR T cell 
populations in the blood versus those present 
in tumor tissue? 
 
How do cancer cells (especially in solid tumors) 
adapt to evade targeting by CAR T cells? 
 1149 
Table 2. Multimodal single-cell tools 1150 
Name Modalities Feature 
coverage 
Throughput Cost References 
      





100-1000 $$$ 48 
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1,000-20,000 $$ 272 
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1,000-10,000 $$ 318 
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